ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2015 American Transplant Congress

    The Immunosuppressive Effect of CTLA4Ig Monotherapy Depends On the Presence of Tregs Only at Suboptimally Low Doses

    C. Schwarz,1 L. Unger,1 B. Mahr,1 K. Aumayr,2 N. Pilat,1 K. Hock,1 A. Farkas,1 I. Kristo,1 T. Wekerle.1

    1Dept. of Surgery, Medical University of Vienna, Vienna, Austria; 2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

    Background: CTLA4Ig/belatacept has been recently approved for immunosuppression after renal transplantation. Concerns persist, however, that a paradoxical dose-response relationship might exist for CTLA4Ig in which…
  • 2015 American Transplant Congress

    Mechanisms Underlying Treg Dysfunction in DAIH- Role for PD-L1?

    A. Arterbery,1 M. Martinez,2 S. Lobritto,2 Y. Avitzur,3 K. Raddassi,1 M. Kleinewietfeld,4 U. Ekong.1

    1Yale, NH; 2Columbia, NY; 3HSC, Toronto, Canada; 4Dresden University of Technology, Dresden, Germany.

    Background: we have previously shown that ex vivo Tregs from patients with DAIH demonstrate differentiation plasticity towards TH17. To understand the mechanisms underlying this we…
  • 2015 American Transplant Congress

    No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up

    M. Zwierzchoniewska,1 K. Fong,1 D. Patel,1 L. Mou, W. Lim,2 B. He,1 L. Delriviere.1

    1Western Australian Kidney Transplant Surgery Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 2Western Australian Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

    INTRODUCTION:Organ shortage remains the single most significant impediment to increasing low rate of kidney transplantation. One of the strategies to improve it, is a utilisation…
  • 2015 American Transplant Congress

    Calcineurin (CNI) Exposure Reduces the Risk of Post-Transplant DSA After Deceased Donor Kidney Transplantation

    R. Pelletier, A. Rajab, G. Bumgardner, M. Henry.

    General Surgery, The Ohio State University, Columbus, OH.

    We use ATG induction with immediate rapamune (Rapa) and delayed CNI immunosuppression following kidney transplantation. Mycophenolic acid (MPA) is substituted for CNI to avoid renal…
  • 2015 American Transplant Congress

    Interleukin-17 Deficiency Attenuates Renal Allograft Injury and Prolongs Survival in a Murine Transplantation Model

    T. Kwan,1,2 S. Chadban,1,2 J. Ma,1,2 S. Bao,2,3 S. Alexander,2,4 H. Wu.1,2

    1Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; 2Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; 3Discipline of Pathology, School of Medical Sciences, Sydney, New South Wales, Australia; 4Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

    Aim:To investigate the role of IL-17 in allograft rejection using a murine model of fully MHC-mismatched renal transplantation.Methods:Life-sustaining kidney transplants were performed in nephrectomized mice:…
  • 2015 American Transplant Congress

    The Effects of Periostin on Renal Fibrosis After Ischemia-Reperfusion Injury Via p38 MAPK Pathway

    J. An,1,2 S. Yang,3 J. Hwang,4 J. Kim,1 S. Kim,2,5 C. Lim,1,2 Y. Oh,1,2 Y. Kim,2 J. Lee.1,2

    1Seoul National University Boramae Medical Center, Seoul, Republic of Korea; 2Seoul National University Hospital, Seoul, Republic of Korea; 3Seoul National University Kidney Research Institute, Seoul, Republic of Korea; 4Chung-Ang University Hospital, Seoul, Republic of Korea; 5Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

    Ischemia-reperfusion injury during the transplantation procedure is associated with poor long-term allograft outcomes, such as rejection and fibrosis. Periostin, a matricellular protein, has been reported…
  • 2015 American Transplant Congress

    Type III Phosphodiesterase (PDE3) Inhibitor Improves Survival Rate After Ischemia Reperfusion Injury of the Liver in Rats

    T. Fujii,1 H. Obara,2 N. Fujimura,2 K. Matsubara,2 Y. Kitagawa.2

    1Surgery, Inagi Municipal Hospital, Tokyo, Japan; 2Surgery, Keio University School of Medicine, Tokyo, Japan.

    BackgroundPDE3 inhibitor (Cilostazol) has long been used as a potent inhibitor of platelet aggregation and thrombosis. Recently, there have been a report on the protective…
  • 2015 American Transplant Congress

    Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations

    T. Elnahhas,1,2 T. Lee,2 M. Moreton,2 D. McKeown,2 J. Popoola,3 R. Ramkhelawon,3 A. Johnston,1,2 I. MacPhee.3

    1Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; 2Analytical Services International, St.George's University of London, London, United Kingdom; 3Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.

    Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…
  • 2015 American Transplant Congress

    Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)

    M. Molina,1 E. Gutierrez,1 S. González-Sanchidrian,2 E. González,1 J. Cabrera,1 N. Polanco,1 A. Hernández,1 A. Sevillano,1 M. Praga,1 A. Andres.1

    1Nephrology, Hospital 12 de Octubre, Madrid, Spain; 2Nephrology, Hospital San Pedro de Alcántara, Caceres, Spain.

    INTRODUCTION: Ischemia injury in kidneys grafts from UDCDD could produce a poor renal function. Minimized blood levels of CNI associated with i-mTOR therapy could avoid…
  • 2015 American Transplant Congress

    Significance of an Isolated Elevated PRA in Renal Transplantation

    S. Kuten, S. Patel, G. Land, T. Eagar, R. Knight, J. Loucks, L. Gaber, A. Gaber.

    Houston Methodist Hospital, Houston, TX.

    Transplant centers have traditionally discerned a patient's immunologic risk based on peak panel reactive antibody (PRA) levels. However, in a given patient, pre-transplant PRA may…
  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • …
  • 170
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences